BELITE BIO INC - ADR (BLTE) Stock News

USA - NASDAQ:BLTE - US07782B1044 - ADR

112.42 USD

+1.34 (+1.21%)

Last: 11/5/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

BLTE Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Virtual Investor Conferences - Mentions: LSE - HCM VIOT ...

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

3 days ago - By: Belite Bio, Inc

Belite Bio to Host Webcast on November 10, 2025, to Discuss Third Quarter 2025 Financial Results

4 days ago - By: Belite Bio, Inc

Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

3 months ago - By: Benzinga

Belite Bio's Earnings Outlook

4 days ago - By: Belite Bio, Inc

Belite Bio Announces UK’s Medicines and Healthcare Products Regulatory Agency Agrees to Conditional Marketing Authorization Application Based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

6 days ago - By: Virtual Investor Conferences - Mentions: HCM LSE - YRD ...

CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

6 months ago - By: Benzinga

Earnings Outlook For Belite Bio

7 days ago - By: Virtual Investor Conferences - Mentions: HCM LSE - YRD ...

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

8 days ago - By: Virtual Investor Conferences; Belite Bio, Inc

Belite Bio to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference November 4th

8 days ago - By: Belite Bio, Inc

Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference

8 days ago - By: Belite Bio, Inc

Belite Bio to Participate in the Deutsche Bank ADR Virtual Investor Conference

21 days ago - By: Belite Bio, Inc

Belite Bio to Participate in the 2025 Maxim Growth Summit

22 days ago - By: Belite Bio, Inc

Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

22 days ago - By: Belite Bio, Inc

Belite Bio Announces China NMPA Agrees to New Drug Application with Priority Review based on Interim Analysis Results for the Treatment of Stargardt Disease with Tinlarebant

2 months ago - By: Belite Bio, Inc

Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease

2 months ago - By: Belite Bio, Inc

Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease

2 months ago - By: Belite Bio, Inc

Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors

2 months ago - By: Belite Bio, Inc

Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors

2 months ago - By: Belite Bio, Inc

Belite Bio to Participate in Three Upcoming Investor Conferences

3 months ago - By: Belite Bio, Inc

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

3 months ago - By: Belite Bio, Inc

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

3 months ago - By: Belite Bio, Inc

Belite Bio Announces Registered Direct Offering of $15 Million

3 months ago - By: Belite Bio, Inc

Belite Bio Announces Registered Direct Offering of $15 Million

3 months ago - By: Belite Bio, Inc

Belite Bio to Participate in the H.C. Wainwright Annual Ophthalmology Virtual Conference

3 months ago - By: Belite Bio, Inc

Belite Bio to Host Webcast on August 11, 2025, to Discuss Second Quarter 2025 Financial Results

4 months ago - By: Belite Bio, Inc

Belite Bio to Participate in the BTIG Virtual Biotechnology Conference

4 months ago - By: Belite Bio, Inc

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

4 months ago - By: Belite Bio, Inc

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

6 months ago - By: Belite Bio, Inc

Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease

6 months ago - By: Belite Bio, Inc

Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease

6 months ago - By: Virtual Investor Conferences - Mentions: VIOT LSE - HCM ...

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

6 months ago - By: Belite Bio, Inc

Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

6 months ago - By: Belite Bio, Inc

Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

6 months ago - By: Virtual Investor Conferences

Belite Bio, Inc to Present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference May 15th